BURLINGTON, Mass., Nov. 12, 2010 /PRNewswire/ -- InfraReDx, Inc. , a medical device company developing intelligent cardiovascular diagnostic imaging technologies, today announced the upcoming presentation of three LipiScan™-related scientific abstracts at the American Heart Association Scientific Sessions 2010 ( AHA 2010 ), being held Nov. 13-17, 2010 at McCormick Place in Chicago. The research being presented includes an oral abstract session focused on cost effectiveness and screening advances, as well as two abstract poster sessions involving InfraReDx's research in the area of lipid core plaque burden and its role in coronary health. Additionally, the company will be exhibiting at booth #950 on Nov. 14-16.
InfraReDx recently launched the LipiScan IVUS Coronary Imaging System, the world's first and only intravascular imaging system that combines and co-registers grayscale intravascular ultrasound (IVUS) with the company's proprietary near infrared (NIR) spectroscopy lipid core plaque (LCP) detection technology, to improve the safety and effectiveness of stenting procedures.
"The role of lipid core plaque in coronary artery disease continues to be a topic of significant medical interest as indicated by the AHA meeting program," said James E. Muller, M.D., founder and chief executive officer of InfraReDx. "We are pleased that the LipiScan IVUS system is now available for use by the cardiology community. The LipiScan component of the multimodality catheter provides a rapid and accurate means to identify lipid core plaque in patients undergoing catheterization. Detection of these plaques is of clinical importance because there is extensive evidence indicating that these lipid core plaques are 'complication-prone' when stenting is performed. In addition, lipid core plaques are suspected to be 'vulnerable plaques' that cau